FDA advisors unconvinced by Reata’s kidney disease drug
pharmaphorum
DECEMBER 9, 2021
An FDA advisory committee has delivered a blow to Reata Pharma, after voting unanimously that the drugmaker’s data on bardoxolone – a drug for kidney disease – did not show it is effective. ” Trading in Reata’s shares was halted ahead of the meeting, but the stock was down 38% pre-market this morning.
52 
Let's personalize your content